Alfred Mann Foundation established to bridge basic research in medicine and to create products that filled unmet and poorly-met needs.
Together with the University of California San Francisco and The Research Triangle Institute, AMF works on the enabling technology for what will become the Clarion® Cochlear Implant.
In collaboration with the Illinois Institute of Technology (IIT) and Queens University in Canada, AMF begins development of a miniature implantable neurostimulator device. AMF works on the hermetically sealed case, IIT on circuitry, and Queens on communication protocol.
AMF and its partners deliver the first prototype of the implantable microstimulator device, which is powered and controlled using radio frequency (RF) and is encased in a glass capsule. A subsequent iteration of the RF-powered microstimulator (RFM) employs a stronger hermetic casing made of ceramic.
Advanced Bionics is formed and receives the license to manufacture and distribute the Clarion® Cochlear Implant.
Medical Research Group (MRG) is formed to work on the long-term glucose sensor, one of AMF’s founding projects.
AMF begins development of a battery-powered microstimulator (BPM) implant, which will have a rechargeable battery, and high-speed two-way telemetry.
AMF licenses microstimulator technology to Advanced Bionics for certain medical applications. Advanced Bionics develops a battery-powered microstimulator device called BION®, which is used in clinical trials for urinary incontinence. Boston Scientific later obtains this license and develops a BION® application to treat migraine headache.
AMF, Illinois Institute of Technology and the Rehabilitation Institute of Chicago form a partnership to develop an Implantable MyoElectric Sensor (IMES) system that could be used to control prosthetic limbs.
RFM Clinical Trials
2003-2005 – clinical trials with the RF microstimulator (RFM) device are conducted in applications relating to obstructive sleep apnea, shoulder subluxation, and post-stroke upper limb hemiplegia.
Bioness, Inc. is established and granted a license to use technology for rehabilitation applications.
2008-2009 – AMF pursues clinical trials with the RFM on lower limb applications for patients with stroke and spinal cord injuries.
Infusion Systems, Inc. and its implantable drug delivery technology is acquired by AMF.
Clinical trials with the RFM are planned for patients suffering from dysphagia as a result of head and neck cancer and for patients with upper limb hemiplegia as a result of traumatic brain injury.
Clinical trials with the Infusion Systems drug delivery system are launched for patients with back pain.